The CD59 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat T lymphocyte cell line, featuring targeted disruption of the CD59 gene. This polyclonal knockout pool provides a heterogeneous loss-of-function model, enabling robust investigation of CD59-dependent complement regulation and T cell receptor (TCR) signaling pathways in a well-characterized immortalized T cell background.
The Jurkat cell line, an immortalized human T lymphocyte line originally established from the peripheral blood of a 14-year-old male with acute T-cell leukemia, serves as a classic model for studying T cell receptor signaling, activation, and apoptosis. Jurkat cells have been extensively utilized to dissect proximal TCR signaling events, including Lck-mediated phosphorylation of ITAMs, ZAP-70 recruitment, and downstream calcium mobilization and MAP kinase cascades, making them an optimal host for knockout analysis of immune regulatory genes.
CD59 encodes a glycosylphosphatidylinositol (GPI)-anchored cell surface glycoprotein that functions as a critical complement regulatory protein by binding to complement components C8 and C9, thereby preventing membrane attack complex (MAC) assembly and protecting host cells from complement-mediated lysis. Beyond complement inhibition, in T lymphocytes CD59 localizes to lipid rafts where it interacts with CD2 and the Src family kinase Lck, promoting lipid raft integrity and facilitating efficient TCR/CD3 signaling, including Lck-mediated phosphorylation of ZAP-70. Expression of CD59 is transcriptionally upregulated by pro-inflammatory cytokines such as TNF-alpha, IL-1beta, and interferon-gamma through STAT3, NF-kB, and Sp1, while its surface expression depends on the GPI anchor synthesis pathway involving PIG-A.
In the Jurkat T lymphocyte context, CRISPR/Cas9-mediated disruption of CD59 removes the cell??s primary defense against complement attack, rendering the knockout cells highly susceptible to complement-dependent cytotoxicity. This sensitization provides a powerful tool for quantifying MAC formation and lytic efficiency in complement activation assays. Furthermore, loss of CD59 disrupts lipid raft organization and impairs CD2?CLck interactions, leading to attenuated TCR signal transduction, as evidenced by reduced Lck kinase activity, decreased ZAP-70 phosphorylation, and altered downstream T cell activation markers such as CD69 expression and interleukin-2 production. This polyclonal knockout population thus enables simultaneous investigation of complement-mediated cell killing and the non-canonical signaling functions of CD59 in T cell biology.
These CD59 knockout Jurkat polyclonal cells are ideally suited for a wide range of research applications. In complement biology, they serve as a renewable source for complement-mediated lysis assays to quantify MAC-dependent cytotoxicity and screen modulators of the terminal complement pathway. The model recapitulates features of paroxysmal nocturnal hemoglobinuria (PNH) and autoimmune hemolytic anemia, enabling disease modeling and therapeutic evaluation. In T cell immunology, the knockout cells facilitate studies on the interplay between complement regulatory proteins and TCR signaling by assessing CD69 upregulation, IL-2 secretion, and Lck/ZAP-70 phosphorylation following CD3/CD28 stimulation. Additional techniques such as co-immunoprecipitation can probe CD2?CLck interactions, while lipid raft isolation reveals changes in membrane microdomain composition. Researchers may also explore viral immune evasion mechanisms that exploit CD59. For detailed specifications or assistance, contact Ascent Research.
